Medtronic Presents Durable Endeavor DES Results At ESC Meeting
This article was originally published in The Gray Sheet
Medtronic's PMA for the Endeavor ABT-578-eluting stent will include data from over 2,800 patients, including three-year follow-up from the 100-patient ENDEAVOR-I trial
You may also be interested in...
Medtronic believes it can capture more than 15% of the international drug-eluting stent market within one year of rolling out its Endeavor in 40 countries outside the U.S
Boston Scientific expects new clinical trial data presented at the Paris Course on Revascularization (PCR) May 24 to help reverse an ongoing shift of the drug-eluting stent market toward Johnson & Johnson/Cordis
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.